Efavirenz induces anergia in animal models for the study of the activational deficits observed in depression : therapeutic effect of the chatecolamine uptake inhibitor bupropion
Ver/ Abrir
Metadatos
Mostrar el registro completo del ítemcomunitat-uji-handle:10234/158176
comunitat-uji-handle2:10234/71324
comunitat-uji-handle3:10234/97314
comunitat-uji-handle4:
TFG-TFMEste recurso está restringido
Metadatos
Título
Efavirenz induces anergia in animal models for the study of the activational deficits observed in depression : therapeutic effect of the chatecolamine uptake inhibitor bupropionAutoría
Tutor/Supervisor
Correa Sanz, MercèFecha de publicación
2016-07-18Editor
Universitat Jaume IResumen
A high degree of behavioral activation and work output are observed in motivated behaviors.
Mesolimbic DA plays an important role in the regulation of this activational component of
motivation. Anergia and fatigue ... [+]
A high degree of behavioral activation and work output are observed in motivated behaviors.
Mesolimbic DA plays an important role in the regulation of this activational component of
motivation. Anergia and fatigue are common symptoms observed in some psychiatric disorders
such as depression. Efavirenz (EFV) is an antiretroviral drug prescribed for HIV-infected
patients. This drug has adverse effects on the CNS, and it produces depressive-like behavior.
EFV has demonstrated to bind to the vesicular monoamine transporter type 2 (VMAT-2) that
can lead to DA depletion. Bupropion is an antidepressant that acts as a DA uptake blocker
effective for the treatment of motivational impairments observed in depressed patients as well as
reverting motivational impairments induced by DA interferences in animals. In animal models,
behavioral activation can be studied using voluntary running wheels (RW) and tasks offering
choices between high effort options leading to highly valued reinforces vs. low effort/low
reward options are used to study effort-based decision making. In the present study we assess
the effect of EFV on behavioral activation as well as the effect of bupropion to revert EFVinduced
motivational impairments.Adult CD1 male mice received EFV (1.25, 2.5, 5 and 10
mg/kg, IP), or EFV (5 mg/kg)-Bupropion (2.5, 5 and 10 mg/kg, IP), and were tested in a RW
and in a T-maze with barrier in the high-density of food arm. Control mice chose to jump the
barrier and consume more sucrose pellets. However, EFV biased animals towards the loweffort/low-reward
option in the T-maze, and dose-dependently reduced voluntary RW activity.
The suppressing effect of EFV on voluntary RW was reversed by the antidepressant bupropion.
EFV induces motivational symptoms in rodents such as anergia and this effect can be reversed
by bupropion. This action may be of interest for the better understanding of the depressive
symptoms observed in HIV patients exposed to EFV. [-]
Palabras clave / Materias
Descripción
Treball Final de Grau en Psicologia. Codi: PS1048. Curs: 2015/2016
Tipo de documento
info:eu-repo/semantics/bachelorThesisDerechos de acceso
http://rightsstatements.org/vocab/CNE/1.0/
info:eu-repo/semantics/restrictedAccess
info:eu-repo/semantics/restrictedAccess
Aparece en las colecciones
- Grau en Psicologia [1100]